WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Additional Paid-In Capital : $3,152 Mil(As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Additional Paid-In Capital?

WuXi Biologics (Cayman)'s quarterly additional paid-in capital stayed the same from Jun. 2022 ($0 Mil) to Dec. 2022 ($0 Mil) but then increased from Dec. 2022 ($0 Mil) to Jun. 2023 ($3,152 Mil).

WuXi Biologics (Cayman) Additional Paid-In Capital Historical Data

The historical data trend for WuXi Biologics (Cayman)'s Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) Additional Paid-In Capital Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial													-	-	-	3,151.76	-

WuXi Biologics (Cayman) Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

WuXi Biologics (Cayman) Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) (WuXi Biologics (Cayman)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (OTCPK:WXXWY) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

WXIBF:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.